We are live on ! Find out more
VAM

Visium Asset Management Portfolio holdings

AUM $1.43B
1-Year Est. Return 3.58%
This Fund
S&P 500
This Quarter Est. Return
-12.03%
1 Year Est. Return
-3.58%
3 Year Est. Return
+100.3%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$7.32B
AUM Growth
+$267M
Cap. Flow
+$1.37B
Cap. Flow %
18.68%
Top 10 Hldgs %
27.6%
Holding
1,433
New
327
Increased
283
Reduced
238
Closed
555

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$306M
2
CI icon
Cigna
CI
+$151M
3
PCRX icon
Pacira BioSciences
PCRX
+$143M
4
ENDP
Endo International plc
ENDP
+$120M
5
THC icon
Tenet Healthcare
THC
+$99.1M

Top Sells

Rank Stock Value
1
ESPR
Esperion Therapeutics
ESPR
+$64.7M
2
BCR
CR Bard Inc.
BCR
+$62.4M
3
PRGO icon
Perrigo
PRGO
+$52.7M
4
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$49.4M
5
SKX
Skechers
SKX
+$47.1M

Sector Composition

Rank Sector Weight
1 Healthcare 50.8%
2 Financials 7.09%
3 Consumer Discretionary 5.97%
4 Energy 5.17%
5 Industrials 4.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ENDP
1
DELISTED
Endo International plc
ENDP
$361M 4.92%
5,204,000
+1,493,276
+40% +$120M
LH icon
2
Labcorp
LH
$25.5B
$327M 4.47%
3,514,090
-412,808
-11% -$42.7M
PRGO icon
3
Perrigo
PRGO
$1.45B
$284M 3.88%
1,804,056
-287,385
-14% -$52.7M
AGN
4
DELISTED
Allergan plc
AGN
$271M 3.7%
+997,201
New +$306M
BHC icon
5
Bausch Health
BHC
$1.68B
$184M 2.51%
1,031,942
+200,525
+24% +$46.8M
CI icon
6
Cigna
CI
$78.9B
$140M 1.91%
+1,037,712
New +$151M
PCRX icon
7
Pacira BioSciences
PCRX
$1.04B
$121M 1.66%
2,951,384
+2,336,584
+380% +$143M
MCK icon
8
McKesson
MCK
$106B
$118M 1.61%
638,054
+364,679
+133% +$77.3M
CNMD icon
9
CONMED
CNMD
$1.32B
$112M 1.53%
2,338,894
-1,106
-0% -$60.7K
AET
10
DELISTED
Aetna Inc
AET
$103M 1.4%
939,759
-290,508
-24% -$33.6M
MNTA
11
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$88.6M 1.21%
5,398,088
+1,256,988
+30% +$25.7M
NBIX icon
12
Neurocrine Biosciences
NBIX
$18.2B
$87.5M 1.2%
2,199,505
+192,322
+10% +$9.3M
THC icon
13
Tenet Healthcare
THC
$22.4B
$85.2M 1.16%
2,306,633
+1,917,250
+492% +$99.1M
HR icon
14
Healthcare Realty
HR
$7.56B
$77.9M 1.06%
3,176,649
+294,550
+10% +$7.27M
ALGN icon
15
Align Technology
ALGN
$12.8B
$77.7M 1.06%
1,369,034
+356,992
+35% +$21.3M
ZBH icon
16
Zimmer Biomet
ZBH
$18.7B
$76.5M 1.04%
838,450
-194,082
-19% -$19.5M
CLVS
17
DELISTED
Clovis Oncology, Inc.
CLVS
$71.9M 0.98%
781,778
+30,955
+4% +$2.68M
SIOX
18
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$66.7M 0.91%
644,895
+9,895
+2% +$1.16M
HYG icon
19
CALL
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
$15.8B
$66.6M 0.91%
+800,000
New +$69.3M
BIIB icon
20
Biogen
BIIB
$31.4B
$65M 0.89%
222,802
+220,092
+8,121% +$72.7M
RARE icon
21
Ultragenyx Pharmaceutical
RARE
$2.5B
$60.8M 0.83%
631,053
-37,185
-6% -$4.26M
AMRI
22
DELISTED
Albany Molecular Research Inc
AMRI
$57.5M 0.79%
3,300,000
+100,000
+3% +$2.04M
ZTS icon
23
Zoetis
ZTS
$33B
$48.1M 0.66%
1,169,262
+248,949
+27% +$11.5M
CBPO
24
DELISTED
China Biologic Products Holdings, Inc.
CBPO
$46.4M 0.63%
516,394
+16,135
+3% +$1.7M
KYNB
25
Kyntra Bio
KYNB
$28.1M
$44.1M 0.6%
80,444
+17,638
+28% +$10.7M
1
2 3 4 5

Similar funds

FBNAT
FirstMerit Bank N.A. Trustee Akron, Ohio $1.24B AUM 5.12% 1-Year Est. Return
CPS
Counsel Portfolio Services Mississauga, Ontario, Canada $1.01B AUM 2.83% 1-Year Est. Return
LH
Lebenthal Holdings New York $806M AUM 2.13% 1-Year Est. Return
CPM
Chesapeake Partners Management Baltimore, Maryland $669M AUM 1.23% 1-Year Est. Return
VFS
VSR Financial Services Overland Park, Kansas $607M AUM 0.85% 1-Year Est. Return
ZA
Zweig Advisers Hartford, Connecticut $586M AUM 1.34% 1-Year Est. Return
FVFIGP
Flagship Ventures Fund IV General Partner Cambridge, Massachusetts $585M AUM
WA
Westport Advisers Westport, Connecticut $542M AUM 2.07% 1-Year Est. Return

Visium Asset Management's Q3 2015 Portfolio in Review

As of Q3 2015, Visium Asset Management held 1,433 positions worth $7.32B, up 3.8% from $7.05B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Visium Asset Management deployed $1.37B of net new capital in Q3 2015, opening 327 new positions and adding to 283 existing holdings. Its largest new stake was Allergan plc: 997,201 shares worth $271M.

By sector, the portfolio is most concentrated in Healthcare at 51% of assets, up from 49% a quarter earlier, followed by Financials and Consumer Discretionary.

On the sell side, the largest reduction was Perrigo, an estimated $52.7M trimmed.

  • Visium Asset Management's largest Q3 2015 buy was Allergan plc: 997,201 shares worth $271M.
  • Visium Asset Management added most to Pacira BioSciences in Q3 2015, an estimated $143M increase.
  • Visium Asset Management's biggest Q3 2015 reduction was Perrigo, cutting an estimated $52.7M.
  • Visium Asset Management fully exited Esperion Therapeutics in Q3 2015, selling an estimated $64.7M.
  • Visium Asset Management's ten largest holdings make up 28% of its $7.32B portfolio in Q3 2015.
  • Visium Asset Management opened 327 new positions and closed 555 in Q3 2015.
  • Visium Asset Management's portfolio value rose 3.8% quarter-over-quarter to $7.32B.

Based on Visium Asset Management's 13F filing for Q3 2015, filed 16 Nov 2015.